Diagnostic Criteria for Invasive Pulmonary Aspergillosis
Invasive pulmonary aspergillosis is diagnosed using a three-tiered classification system—proven, probable, and possible—developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG), with proven disease requiring histopathological documentation plus positive culture from a sterile site, probable disease requiring host factors plus clinical manifestations plus microbiological evidence, and possible disease representing a lower level of diagnostic certainty. 1
Proven Invasive Pulmonary Aspergillosis
Proven IPA requires BOTH of the following:
- Histopathological documentation showing tissue invasion by septate, acute-angle branching hyphae consistent with Aspergillus species on microscopic examination 1
- Positive culture of Aspergillus species from a specimen obtained from a normally sterile site (e.g., lung tissue biopsy, pleural fluid) 1
Important caveat: Histopathological demonstration of hyphae consistent with Aspergillus in the appropriate clinical context can establish proven disease even when culture results are negative, as this occurs fairly frequently 1
Probable Invasive Pulmonary Aspergillosis
Probable IPA requires fulfillment of criteria in ALL THREE categories:
1. Host Factors (Immunocompromise)
- Prolonged neutropenia (absolute neutrophil count <500 cells/μL for >10 days) 1
- Hematological malignancy 1
- Allogeneic hematopoietic stem cell transplantation 1
- Solid organ transplantation 1
- Prolonged corticosteroid use 1
- Emerging risk factors in ICU patients: decompensated liver cirrhosis, COPD, solid tumors, and viral pneumonia (influenza, COVID-19) 2
2. Clinical Manifestations
Radiological findings on chest CT:
- Halo sign (ground-glass opacity surrounding a nodule, indicating hemorrhagic infarction) 1
- Air-crescent sign (crescent of air around a mass, indicating tissue necrosis) 1
- Pulmonary nodules or cavitation 1
- Wedge-shaped, pleural-based infiltrates 1
Clinical symptoms:
3. Microbiological Evidence
Any ONE of the following:
Positive galactomannan (GM) assay from serum or bronchoalveolar lavage (BAL) 3, 1
- Serum GM: cutoff index ≥0.5 provides sensitivity 74% and specificity 85%; cutoff ≥1.0 provides sensitivity 79% and specificity 88% 4
- BAL GM has higher sensitivity than serum, particularly in patients with hematologic malignancies and transplant recipients 3
- Limitation: Mold-active antifungal prophylaxis reduces GM sensitivity 3
Positive β-D-glucan (BDG) assay (requires ≥2 positive levels) 3
Positive Aspergillus-specific PCR from BAL or blood 3
Positive culture of Aspergillus species from sputum or BAL (in appropriate clinical context) 1
Critical exception: Probable IPA can be diagnosed using surrogate non-culture-based methods (positive GM or BDG plus compatible CT findings) in an immunocompromised host with clinical findings of infection, even without organism recovery 1
Possible Invasive Pulmonary Aspergillosis
Possible IPA represents a lower level of diagnostic certainty:
- Host factors present 1
- Clinical manifestations consistent with IPA 1
- BUT microbiological evidence is absent or incomplete 1
Important note: The scope of the "possible" category has been diminished in recent revisions for classically immunocompromised hosts, as it was primarily designed for research classification rather than clinical decision-making 5, 6
Diagnostic Procedures
Recommended invasive procedures for obtaining specimens:
- Bronchoalveolar lavage (BAL): Diagnostic procedure of choice for both adults and children when feasible 3, 1
- Transthoracic percutaneous needle aspiration 1
- Video-assisted thoracoscopic biopsy 1
Specimens should be processed for:
- Direct microscopic examination (looking for septate hyphae with acute-angle dichotomous branching) 1
- Fungal culture on appropriate media 1
- GM testing 3, 4
- PCR testing 3
Common Pitfalls and Caveats
Blood cultures are of limited utility because results are often negative even in disseminated aspergillosis 1
False-negative results occur frequently in patients already receiving systemic antifungal therapy or when diagnostic procedures cannot be performed directly in the affected lung area 1
Invasive procedures may be impractical in patients who are hemodynamically unstable, severely hypoxic, thrombocytopenic, or have advanced coagulation deficits 1
Radiological features (halo sign, air-crescent sign) are characteristic but not diagnostic—other angioinvasive fungi (Zygomycetes, Fusarium, Scedosporium) and even Pseudomonas aeruginosa can produce similar findings 1
These definitions were primarily designed for immunocompromised patients with cancer and transplant recipients and may not be ideal for ICU patients without classical immunosuppression 5, 7
Agreement among different diagnostic algorithms is low (Cohen's kappa 0.07-0.29), and discrimination between invasive infection and Aspergillus colonization remains challenging in critically ill patients 7
Most patients who die with extensive IPA only reach a level of possible or probable disease during life (64% had no microbiological or major clinical criteria before death in one autopsy study), highlighting that these research-oriented definitions should not delay treatment decisions 6
Early initiation of antifungal therapy is warranted in patients with strongly suspected IPA while diagnostic evaluation is conducted, as mortality exceeds 50% in critically ill patients without adequate treatment 8, 4